Difference between revisions of "Serplulimab (Hansizhuang)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: PD-1 receptor antibody. <br>Route: IV <br>Extravasation: no information For conciseness and simplicity, HemOnc.org currently will foc...") |
m |
||
Line 23: | Line 23: | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
− | [[Category: | + | [[Category:NMPA approved drugs]] |
Revision as of 11:17, 30 September 2022
General information
Class/mechanism: PD-1 receptor antibody.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Toxicity management
Diseases for which it is used
Also known as
- Code name: HLX10
- Brand name: Hansizhuang